图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
环境病理学,毒理学和肿瘤学期刊
影响因子: 1.241 5年影响因子: 1.349 SJR: 0.519 SNIP: 0.613 CiteScore™: 1.61

ISSN 打印: 0731-8898
ISSN 在线: 2162-6537

环境病理学,毒理学和肿瘤学期刊

DOI: 10.1615/JEnvironPatholToxicolOncol.v27.i4.10
pages 245-256

Breast Cancer and Ovarian Cancer Genetics: An Update

Richard Edlich
Legacy Verified Level I Shock Trauma Center Pediatrics and Adults, Legacy Emanual Hospital; and Plastic Surgery, Biomedical Engineering and Emergency Medicine, University of Virginia Health System, USA
Catherine L. Cross
Legacy Emanuel Hospital, Portland, OR, USA
Courtney A. Wack
Legacy Emanuel Hospital, Portland, OR, USA
Margot E. Chase
Legacy Emanuel Hospital, Portland, OR, USA
Kant Y. Lin
Department of Plastic Surgery, University of Virginia Health System, Charlottesville, VA, USA
William B. Long III
Trauma Specialists LLP, Legacy Verified Level I Shock Trauma Center for Pediatrics and Adults, Legacy Emmanuel Hospital Portland, OR, USA

ABSTRACT

The purpose of this report on breast cancer and ovarian cancer genetics is to review the evidence for the efficacy of surveillance for early detection, bilateral prophylactic mastectomy, prophylactic oophorectomy, and chemoprevention in preventing breast cancer and improving survival of BRCA1 and BRCA2 carriers. This collective review highlights radiologic screening of patients with this genetic predisposition for cancer as well as discusses cancer risk reduction strategies and reproductive concerns in female BRCA1/2 mutation carriers. It has now been well documented that magnetic resonance imaging (MRI) of the breast has a higher sensitivity than mammography for the diagnosis of breast cancer in patients predisposed to breast cancer. We also emphasize that a new diagnostic device, molecular breast imaging (MBI), is now available and may be as sensitive as MRI. To date, this exciting technology, MBI, has not been used in studies of patients with BRCA1/2 genes. We also discuss in more detail the unique psychological ramifications of female BRCA1/2 mutation carriers. These women face unique choices regarding management of their high risk for breast and ovarian cancer that impact their reproductive options. Despite their high levels of concern, few female BRCA1/2 mutation carriers consider assisted reproduction technologies such as pregnancy surrogate, cryopreservation of oocytes or embryos, or implantation genetic diagnosis to select embryos without BCRA1/2 mutation. Further research must be undertaken to explore the risk management of patients with inherited cancer predisposition and to incorporate these preferences into clinical care.


Articles with similar content:

Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Magnus Bergkvist, Sarah A. Engelberth, Nadine Hempel
Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 5-6
Monica Cheng, Hristos Z. Kaimakliotis, Shaobo Zhang, Catherine R. Miller, Antonio Lopez-Beltran, Michael O. Koch, Yu Yang, Rodolfo Montironi, Liang Cheng
Risk-Reducing Mastectomy
Journal of Long-Term Effects of Medical Implants, Vol.16, 2006, issue 4
Brent C. Faulkner, Richard Edlich, Kathryne L. Winters, Kant Y. Lin
Breast Cancer and Ovarian Cancer Genetics
Journal of Long-Term Effects of Medical Implants, Vol.15, 2005, issue 5
Richard Edlich, Kathryne L. Winters, Kant Y. Lin
Ethics in Osteoporosis and Osteopenia: The Bare Bones of a Surrogate Marker
Ethics in Biology, Engineering and Medicine: An International Journal, Vol.5, 2014, issue 4
Loren Wissner Greene